Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 276Glioblastoma 250Glioma 156Astrocytoma 99Central Nervous System Neoplasms 70Gliosarcoma 69Oligodendroglioma 63Neuroblastoma 63Neoplasms 52Breast Neoplasms 44Melanoma 42Carcinoma, Non-Small-Cell Lung 38Neoplasm Metastasis 33Medulloblastoma 30Lymphoma 29Recurrence 28Lung Neoplasms 27Ependymoma 24Sarcoma 20Ovarian Neoplasms 19Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Meningioma 18Lymphoma, Non-Hodgkin 18Leukemia 18Meningeal Carcinomatosis 17Burkitt Lymphoma 17Multiple Myeloma 16Lymphoma, Large B-Cell, Diffuse 16Diffuse Intrinsic Pontine Glioma 15

Interventions

Corticotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Edema × CNS × Clear all
NCT01369121 2013-07-30

Tolerability Study of Xerecept® in Pediatric Patients

Celtic Pharma Development Services

Phase 1/2 Terminated
15 enrolled
CNS

Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡